• Lifecore Biomedical Inc LFCR.OQ reported a quarterly adjusted loss of 25 cents​​ per share for the quarter ended November 30. The mean expectation of three analysts for the quarter was for a loss of 30 cents per share. Wall Street expected results to range from -34 cents to -27 cents per share.

• Revenue was $32.56 million​; analysts expected $29.75 million.

• Lifecore Biomedical Inc's reported EPS for the quarter was a loss of 25 cents​.

• The company reported a quarterly loss of $8.7 million.

• Lifecore Biomedical Inc shares had held steady so far this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 22% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the pharmaceuticals peer group is also "hold"

Wall Street's median 12-month price target for Lifecore Biomedical Inc is $8.00

This summary was machine generated from LSEG data January 2 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)